ARCHIVES OF MEDICAL SCIENCE, cilt.17, sa.1, ss.1-8, 2021 (SCI-Expanded)
Introduction: To evaluate the efficacy and safety of transition from premixed and intensive insulin to twice-daily insulin degludec/aspart (IDegAsp) co-formulation in patients with type 2 diabetes mellitus.